A detailed history of Gsa Capital Partners LLP transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 96,092 shares of ABEO stock, worth $547,724. This represents 0.05% of its overall portfolio holdings.

Number of Shares
96,092
Previous 62,261 54.34%
Holding current value
$547,724
Previous $264,000 129.92%
% of portfolio
0.05%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$4.12 - $6.32 $139,383 - $213,811
33,831 Added 54.34%
96,092 $607,000
Q2 2024

Aug 15, 2024

BUY
$3.17 - $8.05 $119,509 - $303,485
37,700 Added 153.5%
62,261 $264,000
Q1 2024

May 03, 2024

BUY
$4.07 - $8.68 $99,963 - $213,189
24,561 New
24,561 $178,000
Q3 2023

Nov 15, 2023

BUY
$2.98 - $4.43 $34,681 - $51,556
11,638 New
11,638 $48,000

Others Institutions Holding ABEO

About ABEONA THERAPEUTICS INC.


  • Ticker ABEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,950,380
  • Market Cap $33.9M
  • Description
  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
More about ABEO
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.